Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC) have forged a new alliance to enable adult cancer care.

The partnership will help construct an inpatient hospital in the region for adult cancer patients.

Operating under Dana-Farber's licence, this new hospital will offer adult medical oncology care and create a coordinated clinical and organisational structure in Boston's Longwood Medical Area.

Dana-Farber president and CEO Laurie H. Glimcher said: “Through this collaboration, our patients and their loved ones will benefit tremendously from Dana-Farber’s leading-edge scientific discovery and exceptional patient care.

“We believe this will position us to provide world renowned cancer treatment in outpatient and inpatient settings well into the future.

“Beth Israel Deaconess Medical Center and the physicians of HMFP share our vision and are equally committed to ensuring a superior patient experience and advancing a collaborative focus on world-class cancer care and research that will benefit our region and the world.”

The project awaits regulatory clearance, and is expected to take many years to complete.

Dana-Farber's affiliation with Brigham and Women's Hospital and BIDMC's independent oncology programmes will remain unchanged during the transition.

Outpatient oncology care at Dana-Farber's existing sites will continue, and Beth Israel Lahey Health will also continue its investments cancer services at BIDMC and its other facilities.

Beth Israel Lahey Health president and CEO Kevin Tabb said: “Together, we are taking bold steps to transform how we care for individuals and families touched by cancer, expand equitable access to life-changing care, and harness the power of scientific discovery.

“This collaboration and a dedicated, free-standing cancer hospital will be truly unique in Massachusetts.”